CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

SOPHiA GENETICS Q3 revenue rises on US market strength 

By Reuters News


Overview

  • Switzerland-based AI precision medicine firm's Q3 revenue rose 25% yr/yr

  • Company's adjusted EBITDA loss narrowed 31% yr/yr

  • Company expects 2026 revenue at upper end of guidance, but warns on FX headwind for Q4


Outlook

  • Company expects 2026 revenue at upper end of $94 mln to $96 mln range

  • Company sees 2026 adjusted EBITDA loss between $29 mln and $32 mln

  • Company says foreign exchange rates could weigh on Q4 revenue if trends persist


Result Drivers

  • ANALYSIS VOLUME & BIOPHARMA - Co said record analysis volume, strong U.S. market performance, and BioPharma momentum drove Q3 revenue growth, per CEO Ross Muken

  • VOLUME GROWTH - Record 118,000 analyses performed in Q3, up 19% yr/yr

  • U.S. MARKET - Q3 U.S. revenue rose 41% yr/yr, helping drive overall results


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

$24.30 mln

Q3 Adjusted Gross Margin

72.80%


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"


Reuters Recommended Reads

  • Nov 2 - Switzerland's CRISPR Therapeutics Q3 CASGEVY revenue jumps 30% sequentially

  • Nov 3 - Netherlands' Philips slightly misses Q3 revenue estimates, maintains 2026 forecast

  • Nov 2 - Denmark medical devices maker Coloplast's Q4 revenue rises


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.